Skip to main content

Table 5 Exposure to study opioids and propofol during the maintenance phase (intent to treat population)

From: Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713]

Maintenance phase Remifentanil (n = 77) Fentanyl (n = 75)
Median duration of study opioid infusion (hours; range) 13.7 (2.7–73.0) 14.2 (0.3–73.3)
Weighted mean study opioid infusion rate (μg/kg per hour; range) 9.4 (2.3–22.8) 1.8 (0.5–6.0)
Number of patients receiving the study drug infusion for >24 hours 11 (14%) 10 (13%)
Number of patients who received a propofol infusion 27 (35%) 30 (40%)
Mean time from starting the opioid infusion to starting the propofol infusion (hours; range) 6.6 (0.2–55.6) 5.9 (0.2–38.6)
Median duration of propofol infusion (hours; range) 9.4 (0.6–53.3) 12.0 (2.5–72.3)
Mean % of time patients received a propofol infusion (range) during the maintenance phase 62.8 (3.8–98.9) 76.1 (26.9–99.0)
Median total propofol dose (mg; range) 378.4 (15.8–4690.8) 683.0 (30.0–11323.3)
Weighted mean infusion rate of propofol (mg/kg per hour; range) 0.7 (0.1–2.7) 0.8 (0.2–2.5)
Number of patients receiving the following numbers of propofol bolus doses (n = 27) (n = 30)
   0 18 (67%) 14 (47%)
   1–3 8 (30%) 11 (37%)
   4–6 1 (4%) 4 (13%)
   ≥ 7 0 1 (3%)
Number of patients receiving the following numbers of propofol rate increases (n = 27) (n = 30)
   0 17 (63%) 6 (20%)
   1–3 5 (19%) 14 (47%)
   4–6 3 (11%) 5 (17%)
   ≥ 7 2 (7%) 5 (17%)
Number (%) of patients receiving the following numbers of propofol rate decreases (n = 27) (n = 30)
   0 16 (59%) 18 (60%)
   1–3 9 (33%) 8 (27%)
   4–6 2 (7%) 3 (10%)
   ≥ 7 0 (0%) 1 (3%)